About the Company
Adamas Pharmaceuticals Inc. delivers innovative medicines that reduce the burden of neurological diseases on patients, caregivers and society. The company is a fully integrated company focused on growing a portfolio of therapies to address a range of neurological diseases.
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $ADMS News
Adamas Pharmaceuticals gets grant for extended release amantadine for reducing sleep disturbances in parkinson’s disease
Reduce OFF time in Parkinson's patients with Adamas Pharmaceuticals' patented method using extended-release amantadine. Optimal dosages for improved treatment outcomes.
Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) will be pleased this week, given that the stock price is up 13% to US$3.45 following its latest third-quarter results. Revenues of US$20m ...
Danbury-based biopharmaceutical firm MannKind names new CFO
Before that, he held a series of finance positions of increasing responsibility at the commercial-stage biotech company Adamas Pharmaceuticals Inc., culminating in his appointment as CFO.
Adamas Announces New Employment Inducement Grant
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) today announced that the compensation committee of the company’s board of directors granted five new employees restricted stock units to acquire ...
Supernus bulks up its Parkinson's portfolio with Adamas takeover
Supernus has boosted its position in central nervous system therapies with a $400 million deal to acquire Adamas Pharma that will add two approved Parkinson's disease therapies to its stable.
Competition for Neurocrine as Gocovri picks up new Parkinson's indication
Adamas Pharmaceuticals’ Parkinson’s drug Gocovri has a new indication as an adjunctive treatment for levodopa/carbodopa in patients with Parkinson’s disease experiencing ‘off’ episodes.
Jonathan D Feiber's Net Worth
Inc., Rocket Fuel Inc., SHUTTERFLY INC, Rally Software Development Corp, Adamas Pharmaceuticals Inc, and PROOFPOINT INC. Attention insiders: Dive deeper into market movements and stay ahead of the ...
Terns Pharmaceuticals Appoints Melita Sun Jung as Chief Business Officer
We are excited to welcome Melita to the Terns leadership team at a critical stage of growth at the company,” said Amy Burroughs, chief executive officer of Terns. “With multiple upcoming key ...
XENE Xenon Pharmaceuticals Inc.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical ...
PMVP PMV Pharmaceuticals, Inc.
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product ...
Elite Pharmaceuticals, Inc. (ELTP)
Elite Pharmaceuticals, Inc. (PNK:ELTP) Q3 2024 Earnings Call Transcript February 15, 2024 Elite Pharmaceuticals, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the ...
Vertex Pharmaceuticals Inc VRTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Loading the latest forecasts...